• On April 24, 2026, Indivior Pharmaceuticals presented new real-world data at the 57th ASAM Annual Conference in San Diego, highlighting outcomes for patients with opioid use disorder treated with its monthly extended-release buprenorphine injection, SUBLOCADE.
• The presentation underscored remission, as opposed to abstinence alone, as a key treatment goal, with evidence that sustained, evidence-based therapy may help reduce overdose risk and support more meaningful long-term recovery.
• We’ll now consider how this new real-world evidence around SUBLOCADE’s role in supporting remission could influence Indivior’s longer-term investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior, you have to believe that long acting treatments for opioid use disorder can keep gaining traction and that SUBLOCADE remains central to care. The new remission focused real world data supports Indivior’s clinical story, but it does not obviously change the near term focus on Q1 2026 results and cost discipline, nor does it materially alter the key risk that SUBLOCADE’s long acting injectable penetration could stall below expectations.

Among recent updates, the Feb 26, 2026 reaffirmation of full year 2026 net revenue guidance of US$1,125 million to US$1,195 million is most relevant here. That guidance was set before these ASAM data, so investors will be watching whether management eventually references this new remission evidence when discussing SUBLOCADE’s contribution, particularly as they balance operating expense caps with the need to keep investing behind the product’s growth catalysts.

Yet investors should also be aware that if long acting injectable adoption in opioid use disorder plateaus well below other chronic diseases, then...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and a $353.5 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some analysts were already more optimistic, assuming revenue could reach about US$1.3 billion and earnings around US$596 million by 2029, while also warning that if long acting injectable adoption stalls below expectations, this new remission focused evidence could shift those views in different directions.

Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.